The True Cost of Molecular Diagnostics Adoption.

This section covers the platform-level infrastructure needed to run the instrument itself — storage of raw outputs, network capacity to move data around the lab, and the security posture to handle PHI at scale. Workload infrastructure for bioinformatics processing is covered separately in section 03.

Modern molecular platforms — particularly NGS — generate data at a scale that most clinical lab IT environments were not built to handle. A single high-throughput sequencing run can produce hundreds of gigabytes of raw data. Multiply that across a realistic annual throughput and the storage, compute, and network requirements become significant infrastructure decisions, not IT tickets.

The costs here include local or cloud storage provisioning, compute infrastructure for analysis pipelines, network bandwidth upgrades to move data between instruments, servers, and analysis environments, and — in many clinical settings — the security and compliance infrastructure required to handle PHI at scale. In labs operating under data sovereignty constraints or with unreliable cloud infrastructure, on-premise solutions add hardware procurement and data center costs that cloud-native vendor quotes don't account for.

These costs are often not part of the initial vendor conversation — not because IT was kept out of the room, but because IT wasn't given the complete picture of current and future lab operations to make a fully informed infrastructure recommendation. The on-premise vs. cloud question gets answered based on today's utilization and current data governance constraints. What rarely gets modeled is the infrastructure cost trajectory as throughput scales — and that inflection point can be significant.

Very few molecular platforms land in a greenfield environment. Most labs have an existing software ecosystem — a LIS, an EHR, middleware, instrument control software, billing systems — and every new platform has to connect to some or all of it. The gap between what a vendor's platform does out of the box and what the lab's workflow actually requires is closed by custom code. That code has a price, and it has an ongoing maintenance cost that compounds over the life of the system.

The range is wide and the stakes are high. A lab running 750,000 samples per year through a LIMS held together by custom integration code and a dedicated engineering team is an extreme — but it's a real one. A lab that spent $100K customizing a broad platform for molecular workflows, and now spends another $100K annually maintaining that custom build, made a rational purchase decision with incomplete cost information.

Before purchase, the question to answer is not "does this platform integrate with our LIS?" The question is: "Who will build that integration, what will it cost to build, what will it cost to maintain, and what happens when the vendor releases a major update?"

For NGS specifically, the instrument is only the beginning. The data it produces requires three things to become clinically actionable results: a validated bioinformatics pipeline (alignment, variant calling, annotation, filtering, reporting), the infrastructure to run it (storage for raw and processed data, compute for analysis, and network capacity to move data between instruments and analysis environments), and the ops capability to keep all of it running. All have a real cost. All are frequently underestimated. And all reduce to the same decision a buyer needs to make consciously: build, or buy?

Whether the lab is buying its first sequencer or its fifth, the question is the same. New labs default to "we'll figure it out" and discover the costs mid-implementation. Existing NGS labs that built custom early often keep building because the prior investment has become its own justification — without ever revisiting whether build is still the right answer at current scale.

The build path means in-house pipeline development plus the infrastructure and operations stack that supports it. It buys flexibility — custom panel design, novel variant interpretation, workflow control end-to-end, full ownership of the data architecture — at the cost of building and retaining bioinformatics expertise and infrastructure/ops capability as permanent line items. Pipelines need maintenance as reference databases update, variant calling tools evolve, and clinical interpretation standards change. Infrastructure needs maintenance too: storage scales with cumulative data, compute scales with throughput, and security and compliance posture has to be maintained against a moving regulatory floor. Custom is great until you try to scale it. The cost doesn't grow linearly — it compounds, because each new workflow touches both layers and each existing workflow keeps consuming both.

The buy path typically means leveraging vendor-validated pipelines plus vendor-approved cloud infrastructure for storage and compute. For labs running standard clinical workflows with well-defined assays, this is an increasingly worthwhile tradeoff. Cloud infrastructure scales horizontally and vertically on demand as the lab grows, where local deployments scale much more slowly. The trade is scope: you're limited to the vendor's menu, and you're more susceptible to vendor lock-in. For labs with dynamic or shifting demand — or rapid growth — that tradeoff is often worth the savings in infrastructure build-out.

The expensive failure isn't picking the wrong path. It's never doing the analysis on either layer. Labs commonly do partial analysis — they make a build-vs-buy decision on the pipeline but assume infrastructure will be handled by existing IT. Or they buy vendor cloud and discover that data sovereignty constraints, network bandwidth limits, or reimbursement-driven cost pressure force a rebuild on-premise two years in. Or they build everything custom and find at year three that they're spending more on bioinformatics and infrastructure operations than the original sequencer cost.

Before purchase, the diagnostic question to answer isn't "does the platform have a bioinformatics pipeline." It's: "for every workflow we plan to run on this platform — including ones we'll add in years two and three — what's the build vs. buy answer for both the pipeline and the infrastructure, who owns the work, and what does it cost over three years under each path?" Labs that do that analysis before signing are the ones whose bioinformatics and infrastructure costs match their adoption budget. Labs that don't are the ones running a sequencer at full throughput while their cloud bill quietly outgrows the instrument depreciation.

Molecular diagnostics — and NGS in particular — requires a different operational posture than many of the methodologies it sits alongside in a clinical lab. Vendor training programs cover platform operation. They do not cover workflow integration, laboratory-specific SOP development, or the change management required to shift a team's operational habits.

Factor in the productivity loss during training periods, the cost of running parallel workflows during transition, and the time required for competency documentation, and staff-related adoption costs frequently exceed the line item labs allocate for them by a significant margin.

Clinical laboratories operating under CLIA, CAP, FDA, or equivalent international frameworks cannot simply deploy a new molecular platform and begin reporting results. Method verification, analytical validation, and in many cases full clinical validation are required before a new assay or platform can be used for patient testing. Labs that underestimate the validation timeline are the labs whose implementations take a year when they budgeted for three months.

Regulatory validation is not a soft cost. It has hard resource requirements — staff time, reagent consumption, and documentation overhead — that need to be modeled as part of the adoption budget, not discovered mid-implementation.

Reagent and consumable costs are the most predictable component of molecular platform economics — and still frequently modeled incorrectly at purchase time. Vendor cost-per-sample estimates are typically based on optimal throughput, full batch utilization, and vendor reagent pricing. Real-world labs operate below optimal throughput during ramp-up, run partial batches, and face reagent price changes over multi-year contracts.

Reagent lock-in is a particular risk in platforms with fixed workflow architectures. Model reagent costs against your realistic throughput trajectory — not the vendor's optimistic scenario — and factor in the cost of reagent lock-in if the platform restricts third-party use.

Every month between purchase and full operational go-live is a month of unrealized revenue, unrealized throughput, and continued reliance on whatever the new platform was meant to replace — including send-out testing costs that the in-house platform was acquired specifically to eliminate. This opportunity cost is the most invisible line item in a molecular adoption budget and frequently the largest.

The pre-implementation readiness assessment exists precisely to compress this timeline — by surfacing and resolving the obstacles that cause delays before they occur, rather than after the clock is running.